The HMG20A Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in the NCI-H1975 human lung adenocarcinoma background, designed for disruption of the HMG20A gene. This product provides a mixed population of knockout cells generated by CRISPR/Cas9-mediated gene targeting, enabling functional studies without clonal selection artifacts. HMG20A encodes a chromatin-associated protein that functions as a critical subunit of the RE1-silencing transcription factor (REST) corepressor complex, also known as CoREST. The polyclonal nature of this model supports evaluation of heterogeneous gene-editing outcomes and is suitable for bulk population analyses in cancer biology, epigenetics, and drug resistance research.
The host cell line NCI-H1975 is a well-characterized model of non-small cell lung adenocarcinoma derived from a female non-smoker, harboring activating EGFR L858R and resistance-conferring T790M mutations. These mutations drive constitutive EGFR signaling and are clinically relevant for studying acquired resistance to first- and third-generation tyrosine kinase inhibitors. NCI-H1975 cells are widely employed to investigate mechanisms of EGFR-targeted therapy resistance, epithelial?Cmesenchymal transition, and tumor progression. The genetic background of these cells provides a functionally defined system to examine how epigenetic regulators like HMG20A modulate oncogenic pathways and drug sensitivity in lung adenocarcinoma.
HMG20A functions as a scaffold protein within the REST/CoREST transcriptional repressor complex, where it directly interacts with HDAC1, HDAC2, LSD1, RCOR1, PHF21A, and HMG20B. This complex is recruited to RE1/NRSE sites in genomic DNA by the transcription factor REST, leading to histone deacetylation and demethylation that silences target gene expression. HMG20A is regulated upstream by REST, MECP2, NOTCH1, and SP1, and it mediates repression of downstream neuronal genes such as SYN1, BDNF, and SCN2A, as well as cell-cycle regulators including CCND1 and CDKN1A. Dysregulation of this network has been implicated in oncogenesis, neuronal differentiation defects, and cell cycle control, linking HMG20A to pathways that intersect with NOTCH signaling and chromatin remodeling.
In the NCI-H1975 lung adenocarcinoma model, knockout of HMG20A is expected to derepress REST target genes, potentially altering neuronal gene expression programs and cell-cycle checkpoints that normally restrain proliferation. Given the EGFR-mutant background, loss of HMG20A-mediated silencing may further modulate signaling networks that contribute to drug tolerance or apoptosis evasion. This model enables examination of how epigenetic silencing by the CoREST complex intersects with EGFR-driven oncogenic signaling, providing a platform to dissect resistance mechanisms and identify novel vulnerabilities in NSCLC. The polyclonal configuration preserves natural variation in editing outcomes, reflecting heterogeneous tumor responses observed in vivo.
Typical research applications include chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) to assess REST complex occupancy at target loci, quantitative RT-PCR and western blotting to confirm derepression of downstream targets such as BDNF and CCND1, and RNA-seq to profile transcriptome-wide changes. Functional assays such as cell proliferation, apoptosis, and drug sensitivity testing with EGFR inhibitors further illuminate HMG20A’s role in therapeutic resistance. Immunofluorescence can be used to monitor localization of CoREST components. This product is well suited for functional genomics, epigenetic regulation, and cancer signaling studies. Researchers are encouraged to contact Ascent Research for further technical details and customized support.
